The goal of the American Diabetes Association’s Pathway to Stop Diabetes program is simple, yet revolutionary: find a new generation of scientists at the peak of their creativity, and provide them with the freedom, autonomy, and resources to set them on the road to breakthrough discoveries in translational science that lead to breakthroughs in diabetes science.
The Pathway to Stop Diabetes program is designed to transform diabetes research (link is external)by attracting innovative scientists, physicians, and researchers through financial support and professional mentorship.
Since the program’s inception in 2014, 36 scientists have been selected and 100 percent have secured their first independent faculty positions, 46 invention disclosures and patent applications have been filed, 16 start-ups have been launched, and over 233 manuscripts have been published in peer-reviewed journals by Pathway awardees. After a pause in the program due to the COVID-19 pandemic, the ADA is proud to renew the program and continue fostering new leadership and medical breakthroughs for diabetes research.
ADA's Pathway to Stop Diabetes initiative is transforming diabetes research and improving the lives of people living with diabetes or its burdens.
Each institution is allowed a maximum of one nomination in one of the two available Pathway award types.
Deadlines:
This call for nominations will prioritize translational applications that move knowledge and discovery gained from basic research to its eventual translation into patient and population benefit. The ideal applicant will propose innovative research that will be an important step towards the eventual goal of improving the lives of people at risk of diabetes or living with the disease - and the pathway to this impact is clear. Our vision is to create a pathway to launch the next generation of trailblazers in diabetes research.
Below is a brief summary of the eligibility requirements. Please read the FULL requirements on the American Diabetes Association site.
Initiator: Eligible applicants must currently be in research training positions (post-doctoral fellow, research fellowship). For non-tenure track research positions, (research scientist, research associate) you may be eligible to be nominated if your institution can confirm that your current position is a mentored training position that is not independent (i.e., you are fully supported by your mentor and your employment is dependent upon your mentor).
Accelerator: Awards are available to early-career diabetes investigators proposing innovative and ambitious diabetes-related research programs. Applicants must hold faculty positions and have demonstrated independent productivity in diabetes research. Applicants may currently hold independent NIH funding (K, U or R awards, including an initial R01/U01) but must not have applied for (regardless of outcome), or received, an R01/U01 renewal or a second R01/U01 award. Candidates must be identified through institutional nomination; applications will be accepted only from individuals with the appropriate institution support.
Initiator Awards provide two distinct phases of research support: Phase 1 provides up to two years of support for mentored training at a maximum of $100,000 per year (including 10% indirect costs), Phase 2 provides up to five years of support for independent research at a maximum of $325,000 per year (including 30% indirect costs). Maximum combined support for Phase 1 and Phase 2 is $1,625,000.
The Pathway Accelerator Awards provide five years of research support at a maximum of $325,000 per year (including 30% indirect costs), for a total of $1,625,000.
Owing to the sponsor's restriction on the number of applications that may be submitted from Duke, anyone wishing to pursue nomination should submit the following materials by email to VDBS@duke.edu by June 15th:
